Advancing Liquid Biopsy for Early Cancer Detection.
Accelerating technologies for cancer detection and therapy through a global collaboration between NIT Rourkela, McGill, OU Health, AIIMS, and UdeM.
Core Academic Partners
Active Protocol
ctDNA Analysis v2.4
“Our mission is to accelerate liquid biopsy technologies for cancer detection and therapy, advancing new assays to test patient fluids including blood, urine, and saliva.”
Key Research Areas
We focus on high-impact cancers where early detection through minimally invasive methods can significantly improve survival rates.
Breast Cancer
Developing novel biomarkers for early-stage screening in high-risk populations.
View Studies
Academic & Clinical Partners
NIT Rourkela
Rourkela, India
Lead in biosensor development and TFET-based detection technologies.
McGill University
Montreal, Canada
Leading pediatric projects and diverse liquid-biopsy test validation.
University of Oklahoma
Oklahoma, USA
Stephenson Cancer Center driving biomarker-driven clinical trials.
Université de Montréal
Montreal, Canada
Clinical trials with focus on colorectal and gynecologic cohorts.
AIIMS New Delhi
New Delhi, India
High patient volume studies and cost-effective technology implementation.
Operational Milestones
Foundation & Standardization
Establish governance, standardize SOPs for sample collection across India, Canada, and USA. Initiate pilot data exchange.
Clinical Validation
Launch multi-center clinical trials for breast and cervical cancer. Integrate AI models for data analysis.
Global Expansion
Expansion to additional tumor types and onboarding new international partners. Commercial translation of biosensor tech.
Join the Consortium
Researchers, industry partners, and funding bodies are invited to collaborate.
Global Presence
Connecting labs in USA, Canada, and India.